Commentary: Novel Delivery Approaches for Antiepileptic Drugs: Hope and Hurdles

Neurotherapeutics

Volumn 6, Issue 2, 2009, Pages 381-382

  Schmidt, Dieter ^a   Holmes, Gregory L ^b  

^a Epilepsy Research Group   (Germany)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; DIAZEPAM; GALANIN DERIVATIVE; LORAZEPAM; MIDAZOLAM; NAX 5050; NEUROPEPTIDE Y; PROTIRELIN; SOMATOSTATIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CLONIC SEIZURE; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EPILEPSY; FOCAL EPILEPSY; HUMAN; KINDLING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; EPILEPSY; HUMANS;

EID: 63049136127     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.01.008     Document Type: Article

References (4)

1. Marson A.G., Appleton R., Baker G.A., et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 11 (2007) iii-x, 1
2. Tudur Smith C., Marson A.G., Chadwick D.W., and Williamson P.R. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 8 (2007) 34
3. Schmidt D., and Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
4. Seiffert E., Dreier J.P., Ivens S., et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci 24 (2004) 7829-7836